Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment

by David Parker, Marc-Antoine Belaud-Rotureau
Published 2014-12-01

Micro-cost Analysis of Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment

by David Parker, Marc-Antoine Belaud-Rotureau
Published 2014-01-01

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma

by Solène-Florence Kammerer-Jacquet, Antoine Deleuze, Judikaël Saout, Romain Mathieu, Brigitte Laguerre, Gregory Verhoest, Frédéric Dugay, Marc-Antoine Belaud-Rotureau, Karim Bensalah, Nathalie Rioux-Leclercq
Published 2019-04-01

Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma

by Grégory Verhoest, Thibault Dolley-Hitze, Florence Jouan, Marc-Antoine Belaud-Rotureau, Emmanuel Oger, Audrey Lavenu, Karim Bensalah, Yannick Arlot-Bonnemains, Nicolas Collet, Nathalie Rioux-Leclercq, Cécile Vigneau
Published 2014-01-01

Immunotherapy in Renal Cell Carcinoma: The Future Is Now

by Antoine Deleuze, Judikaël Saout, Frédéric Dugay, Benoit Peyronnet, Romain Mathieu, Gregory Verhoest, Karim Bensalah, Laurence Crouzet, Brigitte Laguerre, Marc-Antoine Belaud-Rotureau, Nathalie Rioux-Leclercq, Solène-Florence Kammerer-Jacquet
Published 2020-04-01